Loading...
•
Jun 30, 2024
Kodiak Sciences Q2 2024 Earnings Report
Reported business highlights and financial results for the quarter ended June 30, 2024.
Key Takeaways
Kodiak Sciences reported a net loss of $45.1 million for the second quarter of 2024, with cash and cash equivalents of $219.2 million at the end of the quarter. The company is focusing on advancing its clinical programs for tarcocimab, KSI-501, and KSI-101, and has strengthened its executive team.
GLOW2 Phase 3 study of tarcocimab in diabetic retinopathy continues to enroll.
DAYBREAK Phase 3 study of tarcocimab and KSI-501 is actively enrolling patients.
APEX Phase 1b study of KSI-101 in patients with macular edema secondary to inflammation is now enrolling patients.
New leadership appointments were made to strengthen the executive team.
Kodiak Sciences
Kodiak Sciences
Forward Guidance
Kodiak believes that its current cash will support current and planned operations into 2026.